RBM3 and ovarian carcinoma: These associations between high RBM3 expression and prolonged oxaliplatin response are in line with previous findings in epithelial ovarian cancer, where a high RBM3 expression was associated with an improved prognosis, and silencing of RBM3 in ovarian cancer cells led to a decreased sensitivity to cisplatin [16].